ReviewCNS drugs2018
Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.
Review in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Rituximab in secondary progressive multiple sclerosis: a meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- Ocrelizumab for multiple sclerosis.The Cochrane database of systematic reviews · 2022Pooled it
- Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.Journal of neurology · 2020Pooled it
- Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Trial
- Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Trial
- Article
- From Phenotypes to Spectrum: Rethinking RRMS, SPMS and PPMS in the Era of PIRA-A Framework Integrating PIRA, Smouldering-Associated Worsening, and Neurologic Reserve to Facilitate Earlier Recognition of Progression.Neurology international · 2026Review
- Integrating big data and artificial intelligence to predict progression in multiple sclerosis: challenges and the path forward.Journal of neuroengineering and rehabilitation · 2025Review
- Effect of impairment on health-related quality of life in people with multiple sclerosis: association of functional systems and EQ-5D-5L index values in a cross-sectional study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials.Neurology · 2025Article
- Exploring the relationship between temperament traits, psychological symptoms, and functional disability assessed with the WHODAS 2.0 in persons with multiple sclerosis.Frontiers in neurology · 2025Article
- Leveraging hand-crafted radiomics on multicenter FLAIR MRI for predicting disability worsening in people with multiple sclerosis.Frontiers in neuroscience · 2025Article
- Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement.Journal of managed care & specialty pharmacy · 2024Article
- Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia.BMC health services research · 2023Article
- Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression.Journal of clinical medicine · 2023Article
- Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.PharmacoEconomics - open · 2023Article
- Recurrent disability progression endpoints in multiple sclerosis clinical trials.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Article
- Neural precursor cells tune striatal connectivity through the release of IGFBPL1.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulating neurological disability has a substantial impact on the lives of patients with multiple sclerosis (MS). As well as the established Expanded Disability Status Scale (EDSS), several other outcome measures are now available for assessing disability progression in MS. This review extends the findings of a previous analysis of relapsing-remitting MS (RRMS) trials published up to 2012, to determine whether there has been a shift in outcome measures used to assess disability in phase III clinical trials in RRMS and progressive MS. Forty relevant trials were identified (RRMS, n = 16; progressive MS, n = 18; other/mixed phenotypes, n = 6). Sustained EDSS worsening, particularly over 3 months, was included as an endpoint in almost all identified trials. Other disability-related endpoints included the Multiple Sclerosis Functional Composite z-score and scores for the physical component summary of the Multiple Sclerosis Impact Scale and Medical Outcomes Study Short-Form (36-item) Health Survey. Tests assessing manual dexterity, ambulation, vision and cognition were also employed, and in some trials, composite endpoints were used. However, there was no obvious trend in choice of disability outcome measures over time. Sustained EDSS worsening over short time periods continues to be the most widely used measure of disability progression in pivotal MS trials, despite its well-recognised limitations. A new tool set is needed for use in MS clinical trials that detects the benefit of potential treatments that slow (or reverse) progressive disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.